Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant (CoQualSEP)

University Hospital, Clermont-Ferrand

Status: Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Treatments: Other: Neuropsychological assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT01392872

CHU-0094

Details and patient eligibility

About

Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in Multiple Sclerosis (MS) but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.

Full description

Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in MS but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Relapsing MS since at least 6 months and less than 10 years
• Neurological state stable since at least 1 month
• Moderate Handicap (EDSS ≤ 5,5)

Exclusion criteria

• Secondary Progressive MS
• Patient having an attack
• Patient having experienced en MS relapse or recovered systemic corticosteroid in the previous 1 month
• Depressive patient

Trial design

48 participants in 1 patient group

sclerosis

Other group

Treatment:

Other: Neuropsychological assessment